In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.
Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study / F. Bartoli, D. Cavaleri, T. Callovini, I. Riboldi, C. Crocamo, A. D(')Agostino, G. Martinotti, F. Bertolini, G. Ostuzzi, C. Barbui, G. Carr(`a), F. Boschello, C. Gastaldon, M.A. Mazzi, M. Nos('e), D. Papola, G. Perini, A. Piccoli, M. Pievani, M. Purgato, M. Ruggeri, F. Tedeschi, S. Terlizzi, G. Turrini, M. Caroleo, P. De Fazio, F. Magliocco, G. Raffaele, M. Chirico, F. Ferrato, I. Limosani, D. Mastromo, E. Monzani, E.G. Ostinelli, M. Porcellana, F. Restaino, P.M. Annese, S. Bolognesi, M. Cerretini, A. De Capua, S. Debolini, M. Del Zanna, F. Fargnoli, A. Giannini, L. Luccarelli, C. Lucii, E. Pierantozzi, F. Tozzi, F. Bardicchia, G. Cardamone, E. Facchi, N. Magnani, F. Soscia, B. Biancosino, S. Zotos, M. Giacomin, F. Pompei, M. Spano, F. Zonta, A. Buzzi, C. Callegari, R. Calzolari, I. Caselli, M. Diurni, E.L. Giana, M. Ielmini, A. Milano, N. Poloni, E. Sani, D. Zizolfi, G. Alberini, P. Bortolaso, S. Cazzamalli, C. Costantini, A. Di Caro, C. Paronelli, S. Piantanida, M. Piccinelli, P. Alessandro, S.V. Barbanti, C. D(')Ippolito, M. Gozzi, V. Moretti, M. Corbo, L. Di Capro, M. di Giannantonio, F. Fiori, M. Lorusso, V. Mancini, D. Viceconte, C. Calandra, M. Luca, M.S. Signorelli, F. Suraniti, B. Balzarro, G. Boncompagni, V. Caretto, R. Emiliani, P. Lupoli, M. Menchetti, E. Rossi, V. Storbini, I. Tarricone, L. Terzi, M. Boso, C. Catania, G. De Paoli, P. Risaro, F. Aspesi, M. Bava, A. Bono, G. Brambilla, G. Castagna, S. Lucchi, R. Nava, M. Provenzi, T. Tabacchi, M. Tremolada, E. Verrengia, M. Barchiesi, M.G. Oriani, A. Aguglia, M. Ferro, L. Ghio, R. Beneduce, L. Laffranchini, L.R. Magni, G. Rossi, G.B. Tura, L. Addeo, G. Balletta, E. De Vivo, R. Di Benedetto, V.F. Parise, B. Carpiniello, F. Pinna, D. Pecile, C. Mattei, T. Bonavigo, E.P. Fabrici, S. Panarello, G. Peresson, C. Vitucci, M. Pacetti, F. Gardellin, S. Strizzolo, E. Cossetta, C. Fizzotti, D. Moretti, L. Di Gregorio, F. Sozzi, G. Colli, D. La Barbera, S. Laurenzi. - In: PSYCHIATRY RESEARCH. - ISSN 0165-1781. - 309:(2022 Mar), pp. 114405.1-114405.4. [10.1016/j.psychres.2022.114405]
Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study
A. D(')Agostino;M. Chirico;I. Limosani;E.G. Ostinelli;M. Porcellana;
2022
Abstract
In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.File | Dimensione | Formato | |
---|---|---|---|
Bartoli et al. - 2022 - Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohyd.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
577.28 kB
Formato
Adobe PDF
|
577.28 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.